Current Report Filing (8-k)
29 December 2021 - 8:16AM
Edgar (US Regulatory)
0001549084
false
0001549084
2021-12-25
2021-12-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
December 25, 2021
Ekso Bionics Holdings, Inc.
(Exact Name of Registrant as specified in
its charter)
Nevada
|
|
001-37854
|
|
99-0367049
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
1414 Harbour Way South, Suite 1201
Richmond, California 94804
(Address of principal executive offices,
including zip code)
(510) 984-1761
(Registrant’s telephone number, including
area code)
Not Applicable
(Registrant’s former name or former
address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock, $0.001 par value per share
|
|
EKSO
|
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 5.02
|
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
|
On December 25, 2021, effective immediately, our
Board of Directors (the “Board”) approved an increase in the size of the Board to seven people and appointed Corinna E. Lathan,
Ph.D. to serve as a director of the Company, with Dr. Lathan’s term to expire as of our 2022 Annual Meeting of Stockholders.
Dr. Lathan has over twenty years of
experience as a leader and technology innovator with deep expertise in human-technology interfaces for robotics and mobile
technology platforms. She co-founded AnthroTronix, a biomedical engineering research and development company that creates diverse
products in robotics, digital health, wearable technology, and augmented reality, and has led it as Board Chair and CEO for over 20
years. She currently serves on the board of PTC, Inc. (Nasdaq: PTC), a global technology provider of Internet of Things and
Augmented Reality platforms, and is a member of its Audit and Cybersecurity Committees. In addition, Dr. Lathan previously served as
Associate Professor of Biomedical Engineering at The Catholic University of America and as Adjunct Professor of Aerospace
Engineering at the University of Maryland, College Park. Dr. Lathan holds a Bachelor’s degree in Biopsychology and Mathematics
from Swarthmore College, a Master’s degree in Aeronautics and Astronautics and Ph.D. in Neuroscience from the Massachusetts
Institute of Technology.
No “family relationship,” as the term
is defined in Item 401(d) of Regulation S-K, exists among Dr. Lathan, on the one hand, and any of the Company’s directors or executive
officers, on the other hand.
On December 28, 2021, the Company issued a press
release announcing the appointment of Dr. Lathan to the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
|
EKSO BIONICS HOLDINGS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Jack Peurach
|
|
Name:
|
Jack Peurach
|
|
Title:
|
Chief Executive Officer
|
Dated: December 28, 2021
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2024 to May 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From May 2023 to May 2024